TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24521695
Drug: Nimotuzumab in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab in combination with radiotherapy
Study: 19949030
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (oMP) 1 g/day for 5 days
Study: 19949030
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IV MP) 1 g/day for 5 days
Study: 17305736
Drug: Short-term topical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term topical steroid treatment (prednisolone acetate 1% eyedrops, stopped after 6 months)
Study: 17305736
Drug: Long-term topical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term topical steroid treatment (prednisolone acetate 1% eyedrops, continued once a day until 12 months postoperatively)
Study: 11797069
Drug: 0.27 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.27 g/kg alcohol
Study: 9766764
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg h.s. adjusted to two tablets by day 10 if needed)
Study: 9766764
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day for all patients initially and 40 mg/day if needed after 6 weeks)
Study: 1912206
Drug: Positive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive treatment (TP) - positive reinforcement focused on quality of life
Study: 1912206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - without therapy
Study: 895528
Drug: Tryptophan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (10 g orally administered)
Study: 31522843
Drug: Antibiotic-impregnated shunt
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated shunt (0.15% clindamycin and 0.054% rifampicin)
Study: 27918333
Drug: Control (Patient-Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Patient-Controlled Analgesic Morphine)
Study: 19808215
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing (QW) of epoetin alfa
Study: 19808215
Drug: Biweekly dosing
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly dosing (Q2W) of epoetin alfa
Study: 19808215
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times per week dosing (TIW) of epoetin alfa
Study: 16710858
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of 500 mg of methylprednisolone
Study: 11316330
Drug: Melatonin secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin secretion estimated by overnight urinary excretion of 6-sulphatoxymelatonin
Study: 2433932
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg, started within 24 hours after onset of stroke, combined with standard treatment (hemodilution using low molecular dextran)
Study: 22186814
Drug: Single-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-visit endodontic therapy
Study: 22186814
Drug: Multiple-visit endodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-visit endodontic therapy
Study: 28902817
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (comprehensive therapy including wearing a compression knee sock, phlebotrophic drugs, and dosed walking)
Study: 18457589
Drug: Transmural collaborative
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transmural collaborative care model including Problem Solving Treatment (PST), workplace intervention, antidepressant medication, and manual guided self-help.
Study: 12141721
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) 220 microg, two sprays/nostril once daily AM
Study: 12141721
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 microg, two sprays/nostril once daily AM
Study: 8867714
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg adrenaline
Study: 8867714
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg adrenaline
Study: 2277735
Drug: Chest physical
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest physical therapy (PT)
Study: 29236943
Drug: Induction TPF
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction TPF (Docetaxel 75 mg/m2 day 1; cisplatin 75 mg/m2 day 1; 5FU 750 mg/m2/day days 1-5) plus concomitant cisplatin-RT (40 mg/m2 weekly)
Study: 26200815
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of methylcobalamin and lidocaine combination for 14 days (A1, B1)
Study: 26200815
Drug: Intramuscular methylcobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular methylcobalamin in addition to local lidocaine injection (A0, B0)
Study: 17607331
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg/day
Study: 15613407
Drug: Recombinant methionyl
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl human leptin (r‐metHuLeptin) administration
Study: 15613407
Drug: Recombinant methionyl
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl human leptin (r‐metHuLeptin) administration for 4 or 16 weeks
Study: 7592204
Drug: Cold dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold dry air inhalation and exhalation
Study: 7592204
Drug: Warm moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm moist air inhalation and exhalation
Study: 25134497
Drug: Automatic Self
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic Self Transcending Meditation (ASTM) plus Treatment as Usual (TAU)
Study: 15996356
Drug: One-piece implants
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece implants (group C)
Study: 11953624
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy focused on the calcified area (4000 impulses, 0.78 mJ/mm2, 2 sessions)
Study: 11953624
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy focused on the origin of the supraspinatus tendon (4000 impulses, 0.78 mJ/mm2, 2 sessions)
Study: 1993631
Drug: Misonidazole 1
Normalized name: metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole 1 g/m2 with 3.0 Gy x 10 fractions
Study: 1993631
Drug: Misonidazole 2
Normalized name: metronidazole 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole 2 g/m2 with 5.0 Gy x 6 fractions
Study: 6524276
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 60 ml mepivacaine 1% with adrenaline
Study: 6524276
Drug: Fractional injections
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional injections of 30 + 30 ml mepivacaine 1% with adrenaline (20 min interval)
Study: 6524276
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Bolus and Fractional injections)
Study: 31048271
Drug: Pharmacist implemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist implemented educational treatment programme
Study: 29027034
Drug: Low-intensity LED
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity LED therapy (λ 640 ± 20 nm, 6 J/cm2)
Study: 24619865
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) consumption (75 mg EGCG)
Study: 12665537
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g/day)
Study: 10823096
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg i.v.
Study: 10690141
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 ml i.v. (Control)
Study: 31553815
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF)
Study: 27380540
Drug: Siponimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod 1.25 mg
Study: 27380540
Drug: Siponimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod 0.5 mg
Study: 27380540
Drug: Siponimod 0.25
Normalized name: siponimod 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod 0.25 mg
Study: 20356491
Drug: Single-agent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent gemcitabine (1000 mg/m² at Days 1 and 8 for a 21-day cycle)
Study: 20356491
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus carboplatin (gemcitabine 1000 mg/m² at Days 1 and 8 and carboplatin AUC5 at Day 2 for a 21-day cycle)
Study: 18565577
Drug: Online cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online cessation intervention with $10 weekly incentives and personalized smoking cessation messages.
Study: 15976151
Drug: CBT+fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT+fluoxetine
Study: 10621762
Drug: Venlafaxine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (200-300 mg/day)
Study: 10621762
Drug: Paroxetine (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30-40 mg/day)
Study: 8187120
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg daily
Study: 1687407
Drug: Steroids before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids before streptokinase infusion
Study: 1687407
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin and oral anticoagulants
Study: 6355181
Drug: Dazoxiben 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben 200 mg
Study: 6355181
Drug: Dazoxiben (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben (25, 50, 100, 200 mg)
Study: 30497093
Drug: Antioxidant administration
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant administration (α-lipoic acid, vitamin C and E)
Study: 30497093
Drug: Antioxidant administration
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant administration in hypoxia
Study: 28204880
Drug: γ‐cyclodextrin curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ‐cyclodextrin curcumin formulation (CW8)
Study: 28204880
Drug: curcumin phytosome
Normalized name: Jarrow Formulas Curcumin Phytosome Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcumin phytosome formulation (CSL)
Study: 28204880
Drug: formulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: formulation of curcumin with essential oils of turmeric (CEO)
Study: 14984727
Drug: Pentoxifylline 600
Normalized name: pentoxifylline 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 600 mg BID (n=23)
Study: 11590517
Drug: nelfinavir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir (750 mg tid), saquinavir soft-gel capsule (SGC) (800 mg tid), and stavudine (40 mg bid)
Study: 11590517
Drug: ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritonavir (400 mg bid), saquinavir-SGC (400 mg bid), and stavudine (40 mg bid)
Study: 11590517
Drug: delavirdine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: delavirdine (400 mg tid), saquinavir-SGC (800 mg tid), and stavudine (40 mg bid)
Study: 19647342
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g)
Study: 8082093
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin (60 mg/m2) or carboplatin (300 mg/m2), epirubicin (50 mg/m2), etoposide (100 mg/m2) and local irradiation (15 Gy total)
Study: 8082093
Drug: Carboplatin treatment
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin treatment
Study: 2672755
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus relaxation and breathing therapy (treatment A, n = 76)
Study: 2672755
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training only (treatment B, n = 80)
Study: 2672755
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus relaxation and breathing therapy (treatment A)
Study: 3319629
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training only (treatment B)
Study: 28795831
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy for Suicide Prevention (PST-SP)
Study: 23190794
Drug: Carvedilol +
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol + Lisinopril
Study: 17344670
Drug: Weekly infusional
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly infusional 5FU (WI-FU)
Study: 6293716
Drug: Regimen 1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1 (10% mannitol, oral neomycin, intravenous cefotaxime)
Study: 6293716
Drug: Regimen 2
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2 (10% mannitol, oral neomycin, intravenous cefotaxime for 24 hours postoperatively)
Study: 6293716
Drug: Regimen 3
Normalized name: Bayer Aspirin Regimen 325mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 3 (10% mannitol, oral neomycin, cefazolin sodium)
Study: 30798587
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation with sofosbuvir and ribavirin (Group B)
Study: 23713245
Drug: Guizhi Fuling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guizhi Fuling Pill (GFP) and earthworm powder (Group A)
Study: 11773907
Drug: Low-dose milrinone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose milrinone (25 microg/kg intravenous bolus over 60 minutes followed by a 0.25 microg/kg/min infusion for 35 hours)
Study: 11773907
Drug: High-dose milrinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose milrinone (75 microg/kg intravenous bolus over 60 minutes followed by a 0.75 microg/kg/min infusion for 35 hours)
Study: 9650437
Drug: Standford Hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered after cold pressor pain protocol
Study: 9650437
Drug: Standford Hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered before cold pressor pain protocol
Study: 7648148
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin plus metronidazole
Study: 2667860
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (carisoprodol, paracetamol, and caffeine)
Study: 31087313
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of colostrum (0.2 mL, 0.1 mL on either side, every 2 hours for 72 hours)
Study: 31010430
Drug: LAFEW 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAFEW 8 g group
Study: 31010430
Drug: LAFEW 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAFEW 6 g group
Study: 31010430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (8 g of milk whey protein)
Study: 21442610
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (historical and concurrent national controls)
Study: 19558521
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) on mode
Study: 19558521
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) off mode
Study: 8172113
Drug: Single nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nutrients with antihypertensive properties
Study: 2697484
Drug: Phenobarbitone (PB)
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (PB) therapy
Study: 2697484
Drug: Sulphonylureas (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylureas (SU) plus metformin (M)
Study: 341301
Drug: Ibuterol 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuterol 0.75 mg
Study: 341301
Drug: Terbutaline 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.50 mg
Study: 16045526
Drug: Standard MEA
Normalized name: COCAMIDE MEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MEA treatment after drug preparation
Study: 12230594
Drug: MIG-99 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIG-99 6.25 mg t.i.d.
Study: 12230594
Drug: MIG-99 (2.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIG-99 (2.08 mg; 6.25 mg; 18.75 mg t.i.d.)
Study: 10025454
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with intravenous conscious sedation and monitored anesthesia care
Study: 7788826
Drug: 0.05 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg‐1 morphine plus 3 micrograms.kg‐1 clonidine (M+C group; n = 10)
Study: 7788826
Drug: 0.05 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg‐1 morphine alone (M group; n = 10)
Study: 2204698
Drug: rgp160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rgp160 vaccine (40 or 80 micrograms)
Study: 2204698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hepatitis B vaccine and placebo)
Study: 913279
Drug: Aminophenazone two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophenazone two hours after oral intake in healthy children (control group)
Study: 31571367
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser ablation combined with topical 5% 5-flurouracil application followed by NB‐UVB sessions for 4 months
Study: 31012565
Drug: Red deer
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red deer mesenchymal stem cell extract (RCE) cream
Study: 24145742
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (10 g over 3 to 5 days, or 8 g over 2 days)
Study: 22111516
Drug: Blueberry (BB)
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry (BB) ingestion (250 g per day for 6 weeks and 375 g 1 hour prior to exercise)
Study: 19927100
Drug: ProDisc-L (TDR)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L (TDR) at L4/5
Study: 19927100
Drug: ProDisc-L (TDR)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L (TDR) at L5/S1
Study: 16987338
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (group L)
Study: 12722962
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg and 120 mg
Study: 10657410
Drug: Hypervolemic (HV)
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypervolemic (HV) therapy
Study: 10657410
Drug: Normovolemic (NV)
Normalized name: NV-354
DrugBank: NV-354 (DB18392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic (NV) therapy
Study: 10657410
Drug: Both HV
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HV and NV therapy
Study: 9071714
Drug: Danaparoid sodium
Normalized name: Danaparoid Sodium
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danaparoid sodium (750 anti-Xa units subcutaneously once-daily for 6 weeks)
Study: 2428948
Drug: VAB-6 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAB-6 chemotherapy regimen (cyclophosphamide, vinblastine, bleomycin, dactinomycin, and cisplatin)
Study: 2428948
Drug: VAB-6 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAB-6 chemotherapy regimen
Study: 25885841
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% at 2 mg/kg body weight with 50 μg fentanyl
Study: 25885841
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% at 2 mg/kg body weight with 100 μg fentanyl